Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,465 total articles
Meta's Muse AI agent has already moved the needle on sentiment and user engagement. The market is treating Muse like a subscription experiment; we argue its advertising signal capture and higher CPM potential are worth far more. Trade idea: buy META at $750.60 with a $900 target and $690 stop for a long-term position (180 trading days).
XPeng trades near its 52-week low with a $9.7B market cap despite clear traction in deliveries, rising NEV penetration, and a growing software and robotics roadmap. This trade targets the company's robotics and robotaxi optionality as the asymmetric upside while using EV and ADAS execution as the nearer-term value support. Entry, stop, and target a…
SELLAS Life Sciences (SLS) is a small clinical-stage oncology shop trading at $11.66 after a pullback tied to a regulatory/investor probe story. The setup is a swing trade: buy the dip into improving technical support, leverage an elevated short-interest backdrop and upcoming potential readouts, while sizing for binary clinical and legal risk. Entr…
Oracle has been accused of being slow to the cloud and AI party, but its underlying cash generation, sticky enterprise contracts, accelerating OCI traction, and aggressive capital return make short-term execution noise a buying opportunity. This trade idea lays out a clear entry, stop, and target for a 180-trading-day campaign to capture a valuatio…
AMD has been through multiple inflection points: server share gains with EPYC, GPU expansion for data center workloads, and continued strength in client processors. After a period of consolidation, the next material leg higher looks like it will be driven by another enterprise AI ramp and product cadence in 2026. This trade idea offers an actionabl…
Starbucks has checked the boxes on digital and daypart execution, posted consecutive comp growth, and sits on solid cash flows. Valuation is rich but technicals show oversold conditions and catalysts — from a near-complete digital menu rollout to upcoming results — make a mid-term long trade attractive. Upgrade to BUY for a mid-term (45 trading day…
Five9's core contact-center business is generating meaningful free cash flow and the stock has recovered from its spring lows as AI conversations push re-rating. The fundamentals support a mid-term long trade: entry $36.50, stop $32.00, target $44.00 over ~45 trading days, with a clear plan for when to reassess.
Credo (CRDO) just launched 224G ZeroFlap optics and is guiding for very large optical revenue potential in fiscal 2027. The stock’s current pullback offers a tactical long with clear upside to the recent 52-week high if execution and hyperscaler ramps proceed. Valuation is rich, so position sizing and a strict stop are essential.
Atlassian's recent operational momentum - double-digit cloud growth, record large deals and a rising ARR - has the stock trading near its 52-week high. Fundamentals point to durable growth, but at a market cap near $48.7B and a price-to-sales of 7.4 the stock is no longer a cheap bet. This trade idea recommends a measured long with a clear stop and…
I sold Uber in March after a run-up. The stock has pulled back into the high-$60s, trading at roughly 14.8x trailing earnings with $9.44B in free cash flow and a $141B market cap. That combination of profitability, cash generation and a manageable capital structure justifies re-entering on a long-term trade plan. This note explains the thesis, valu…
Tencent combines scale in games, social and payments with accelerating AI adoption across content, cloud and ad products. At $55.80 the shares trade at a P/E of 15.1 with a $507.5B market cap. This trade targets a bounce toward $68 over a mid-term horizon (45 trading days) while protecting capital near the 52-week low.
AstraZeneca (AZN) trades below its 52-week high but shows improving earnings momentum, a diversified oncology-heavy pipeline and stable free cash flow. Valuation is reasonable relative to growth runway; a disciplined long with a $155 stop and $190 target balances upside and headline risks over a multi-month position.
Southwest Gas (SWX) looks attractively valued after a string of operational resets and a dividend raise. At $81.37 the stock trades at ~11.3x 2026 EPS and yields ~3.1%. Technicals are oversold and short interest is elevated, setting up a potential mean-reversion trade. The key counterbalance is negative free cash flow and continuing rate-case/regul…
Taiwan Semiconductor (TSM) sits at the center of the AI hardware boom. With sustained capital spending tied to AI and advanced nodes, improving technicals, and a market cap of ~$2.34 trillion that still looks reasonable versus future earnings power, TSMC merits a long trade. Entry $455.16, target $520.00, stop $420.00 — horizon 180 trading days.
Air Canada is a high-conviction buy even after a renewed oil shock. The combination of sustained leisure demand, network flexibility, strong brand/loyalty, and the ability to pass fuel-driven costs through fares argues for a rebound. This trade targets a meaningful rebound in the next 180 trading days while accepting near-term volatility.
Meta's recent product cadence — Muse AI agent and a big push in AI glasses — has catalyzed a re-rating. Fundamentals (strong free cash flow, healthy ROE, low leverage) and technical momentum support a long-term trade. This plan targets $900 with a $730 stop over 180 trading days, balancing upside from ad monetization and hardware lift against valua…
TTM Technologies (TTMI) is showing clearer signs of sustainable, high-single to double-digit growth as N+M PCB technology ramps toward an expected $600M run-rate in H2 2026 and data-center sales accelerate. The stock trades at a premium multiple today, but balance-sheet stability, improving yields and an accretive European acquisition plan create a…
Berkshire Hathaway remains a uniquely diversified cash machine trading at reasonable multiples for a $1.08T conglomerate. Management continuity on capital allocation plus recent opportunistic buys give investors a clear, actionable long trade: enter near $759,702, stop at $698,000, target the 52-week high at $806,102 over a long-term (180 trading d…
A widely cited $30 billion 'bill' tying Alphabet to SpaceX sounds scary, but the economics and Alphabet's balance sheet make the figure far less threatening than headlines suggest. This trade targets the short-to-mid-term recovery once investors digest that the commitment is likely staged, contingent, or non-cash. Entry $340, stop $320, target $380…
Carrier (CARR) is levered to a structural surge in data-center cooling and appears to be entering a short-cycle operational recovery. At $55.57 today the stock offers a tradeable asymmetric return: continued backlog-led order growth and cash generation justify a target near $66.50 while near-term weakness below $50 should force an exit. Technicals …
ASE Technology (ASX) sits at the center of the AI-driven shortage in advanced packaging capacity. With valuation stretched versus historical ranges but fundamentals and technicals supportive, this trade idea targets an entry on a mild pullback and a mid-term hold as LEAP and other capacity expansions ramp.
FedEx (FDX) has been punished aggressively, leaving the stock trading at ~$280 with a P/E ~15 and free cash flow of roughly $5.1B. Technicals show deep oversold readings and elevated short activity. The market appears to be pricing in a clean FedEx Freight quarter that the company has not consistently produced. We see a tactical, risk-managed long:…
Rocket Lab has locked financing and is pushing to close its acquisition of Iridium. The strategic fit - instant scale, recurring government and enterprise cash flows, and Iridium's global L-band network - creates a credible willingness to pay up. For traders, IRDM offers a defined, event-driven long opportunity with asymmetric upside if the deal or…
Solid Biosciences (SLDB) presents a high-conviction long trade at $7.48. The company has rebuilt balance-sheet resilience, broadened capsid licensing and program exposure, and is positioned to capture upside as Duchenne screening, regulatory designations and partnerships compress risk. Entry $7.48, target $11.45, stop $5.50. Time horizon: long term…
Sendas (ASAIY) finished a multiyear expansion of its low-cost Assaí chain and is trading near the top of its 52-week range at $9.72. With a $2.63B market cap, a trailing P/E of 14.4 and improving technicals, the risk/reward favors a long bias. This trade idea offers a clear entry at $9.72, stop at $8.50 and target at $12.50 over a long-term (180 tr…
